Business Wire

Nymi Launches Next-Gen Wearable Authenticator For Passwordless MFA in OT Environments

4.2.2025 13:00:00 EET | Business Wire | Press release

Share

Nymi, Inc. today announced the launch of its next-generation wearable authenticator, the Nymi Band 4, which introduces design upgrades and expanded passwordless use cases for regulated industries, while retaining its core authentication functionality that has made it a leading solution in the life sciences manufacturing sector.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250204711667/en/

Meet Nymi Band 4 (Photo: Business Wire)

This latest development from Nymi offers industries with complex operations a handsfree solution for passwordless, Multi-Factor Authentication (MFA) that delivers strong security, compliance, and convenience for deskless workers, including manufacturing line operators, laboratory scientists, field technicians, and other critical workers in process-intensive environments.

The Nymi Band 4 is available for use as a standalone FIDO2 authenticator, or as part of the Nymi Connected Worker Platform to enable customized use cases and seamless integration with other systems.

“What we have continually heard from our life sciences customers is that most authentication solutions don’t work for all their workers and environments, particularly those outside of a traditional office setting,” said David Fortune, President of Nymi. “Nymi has been designing and delivering a handsfree passwordless solution for the 80% of the global workforce who are deskless workers, often sharing terminals and devices, and who work on their feet or use their hands to perform their jobs.”

With the latest iteration of the Nymi Band 4, Nymi has produced their most advanced workplace wearable yet, incorporating feedback and insights from their expanding customer base, which includes 14 of the top 15 global pharmaceutical manufacturers.

“We anticipate additional industries will adopt the Nymi Band because it makes life easier for their workers,” Fortune continued. “By offering a best-in-class solution tailored to an often-overlooked workforce, the Nymi Band also helps organizations meet stringent compliance standards, strengthen security, ensure data integrity, and embrace Industry 4.0 with on-the-person authentication—also known as the connected worker.”

Beyond life sciences, demand for the Nymi Band has been growing in other critical industries, as major companies look to save time, bolster security, and alleviate password-related frustrations for their workforce.

The launch of the Nymi Band 4 solidifies Nymi’s commitment to empowering deskless workers in OT environments with innovative, secure, and user-friendly authentication solutions. By addressing the unique challenges faced by life sciences manufacturing and other industries, the Nymi Band 4 opens new opportunities for digital transformation and operational efficiency.

To learn how the Nymi Band 4 can transform your workplace authentication, visit www.nymi.com or schedule a demo today.

About Nymi

Nymi, a subsidiary of Innominds, is a pioneer in wearable authentication solutions, delivering innovative, passwordless technology that empowers deskless workers in OT environments. The Nymi Band™ offers a secure, handsfree experience that seamlessly integrates with enterprise applications, systems, and networks. By combining biometric, continuous, and Multi-Factor Authentication (MFA) capabilities, the Nymi Band supports robust security, regulatory compliance, and operational efficiency—all while enhancing worker satisfaction.

Trusted by 14 of the top 15 global pharmaceutical manufacturers, Nymi’s solutions are designed to address the unique challenges of process-intensive industries, from secure access control to e-signatures and digital workflows. Supported by an extensive ecosystem of technology partners—including Eviden, Microsoft, Rockwell Automation, and Siemens—Nymi enables organizations to reimagine IT/OT authentication, paving the way for a connected and secure future that prioritizes the deskless worker.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250204711667/en/

Contacts

Joy Cho
Nymi
Marketing
+1 416-977-3042
jcho@nymi.com

Anjan Jayasimha
Innominds
Head of Media Relations & Branding
+1 408-434-6463
anjanj@innominds.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye